Articles and Insights About Wearables for Clinical Trials

The adoption of wearables into clinical trials is fostering innovative ideas about novel digital biomarker development. The following articles discuss strategies for developing respiratory endpoints using real-world data and a patient-centered approach. Learn more and advance ideas for your next research project!

Respiratory abnormalities characterize a variety of disorders. In addition to physical disorders, ventilation is profoundly affected by mental and psychophysiological states, including stress, anxiety, and panic disorder. Let’s take a look at respiratory-related health issues and the promising wearable technology available to assess respiratory outcome measures in real-world settings.

Severe respiratory disease is one of the leading causes of infant illness and death worldwide. There is a significant upward trend of clinical infant respiratory studies, including the investigation into respiratory success in ventilated infants, SIDS, and neurological disorders that affect the normal respiratory pattern. In this article, we discuss how noninvasive respiratory monitoring and VivoSense^® software helps researchers collect and analyze respiratory data for clinical studies focused on infant and neo-natal breathing patterns.

Respiratory inductance plethysmography (RIP) is a method for evaluating breathing characteristics by measuring the movement of the thorax and abdominal wall. RIP acquires respiratory data via two elastic bands placed around the rib cage (RC) and abdomen (AB), and thus, must be calibrated to provide accurate volume metrics.

VivoSense continues to lead the way in infant respiratory analysis.

Orange County, CA, February, 2017 – Washington University School of Medicine, and St Louis Children’s Hospital with funding from the NIH Prematurity and Respiratory Outcomes Project (PROP) https://clinicaltrials.gov/ct2/show/NCT01435187 have published early research findings. The primary goal of the PROP study was to identify biomarkers and clinical variables in premature infants that would potentially predict pulmonary status up to one year later.

Roche’s Firefish clinical trial will evaluate drug efficacy against respiratory muscle function and breathing patterns in infants treated for SMA.

Orange County, CA, January, 2017 – Vivonoetics Inc., developer of VivoSense® respiratory testing solutions, announced today that in partnership with Great Lakes NeuroTechnologies, they will be providing advanced respiratory assessment to the Roche FIREFISH study.